Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

ClinicalTrials.gov ID: NCT01431391

Public ClinicalTrials.gov record NCT01431391. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Non-metastatic Prostate Cancer and a Rising Serum Prostate Specific Antigen After Primary Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study was to determine whether ADT started before or after sipuleucel-T led to a better immune system response. This study also evaluated the safety of sipuleucel-T and ADT treatment, immune system responses over time, the characteristics of sipuleucel-T, and changes in prostate specific antigen (PSA) values over time.

Study identification

NCT ID
NCT01431391
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Dendreon
Industry
Enrollment
68 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2011
Primary completion
Nov 30, 2014
Completion
Nov 30, 2014
Last update posted
May 29, 2017

2011 – 2014

United States locations

U.S. sites
14
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Urology Center of Alabama Homewood Alabama 35209
University of California San Diego / Moores Cancer Center La Jolla California 91914
Keck Hospital of USC Los Angeles California 90033
LAC + USC Medical Center Los Angeles California 90033
USC / Norris Comprehensive Cancer Center Los Angeles California 90033
The Urology Center of Colorado Denver Colorado 80211
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21287
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169
NYOH Albany Cancer Center at Patroon Creek Albany New York 12206
Community Care Physicians, PC Albany New York 12208
Grand Strand Urology Myrtle Beach South Carolina 29572
Urology San Antonio Research San Antonio Texas 78229
Virginia Mason Medical Center Seattle Washington 98101
Seattle Cancer Care Alliance Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01431391, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 29, 2017 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01431391 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →